Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 377

1.

Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.

Perfetto EM, Subedi P, Jumadilova Z.

Am J Manag Care. 2005 Jul;11(4 Suppl):S150-7.

2.
3.

Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.

Nitz NM, Jumadilova Z, Darkow T, Frytak JR, Bavendam T.

Am J Manag Care. 2005 Jul;11(4 Suppl):S130-9.

5.
6.

Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.

Jumadilova Z, Varadharajan S, Girase P, Ollendorf DA.

Am J Health Syst Pharm. 2006 Dec 1;63(23):2357-64.

PMID:
17106009
7.

Persistence with overactive bladder pharmacotherapy in a Medicaid population.

Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z.

Am J Manag Care. 2005 Jul;11(4 Suppl):S121-9.

8.

Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.

O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T.

Clin Ther. 2001 Dec;23(12):2038-49.

PMID:
11813937
10.
11.

Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.

Homma Y, Paick JS, Lee JG, Kawabe K; Japanese and Korean Tolterodine Study Group.

BJU Int. 2003 Nov;92(7):741-7. Erratum in: BJU Int. 2004 May;93(7):1135.

13.

Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.

Getsios D, El-Hadi W, Caro I, Caro JJ.

Pharmacoeconomics. 2005;23(10):995-1006. Review.

PMID:
16235973
14.

Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.

Bolge SC, McDonnell DD, Chen A, Wan GJ.

Curr Med Res Opin. 2007 Aug;23(8):1903-12. Review.

PMID:
17610806
15.

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.

Hart WM, Abrams P, Munro V, Retsa P, Nazir J.

J Med Econ. 2013 Oct;16(10):1246-54. doi: 10.3111/13696998.2013.829079. Epub 2013 Sep 11.

PMID:
23885660
16.

Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data.

Hall JA, Nelson MA, Meyer JW, Williamson T, Wagner S.

Manag Care Interface. 2001 Aug;14(8):69-75.

PMID:
11517841
17.
18.

A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.

Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN.

Manag Care Interface. 2000 Feb;13(2):88-94. Review.

PMID:
11067391
19.

Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.

Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z; 037 Study Group.

Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17.

PMID:
18639327
20.

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH; OPERA Study Group.

Mayo Clin Proc. 2003 Jun;78(6):687-95.

PMID:
12934777

Supplemental Content

Support Center